Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

15.04.2020 | review | Ausgabe 2/2020 Open Access

memo - Magazine of European Medical Oncology 2/2020

The intestinal microbiota and hepatocellular carcinoma

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 2/2020
Autoren:
Maria Effenberger, M.D. Herbert Tilg
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Hepatocellular carcinoma (HCC) is an aggressive malignancy developing from underlying chronic liver disease (CLD). HCC has become the third leading cause of cancer mortality worldwide [ 1]. Underlying diseases differ between low- and high-income countries. While viral hepatitis is the leading cause in low-income countries, alcoholic (ALD) and nonalcoholic (NAFLD) fatty liver disease represent the most frequent cause in the western hemisphere [ 2]. The pathogenesis is diverse, driven by a vicious circle of liver injury, inflammation and regeneration.
The understanding of genetically associated HCC development changed completely through genome wide association studies (GWAS). Useful suggestions on signaling pathway of tumor development were discovered through these genetic associations [ 3]. But these studies could not clarify the functional understanding of HCC. The current model of disease is a combination of predisposing factors and genetic risk. The bacterial microbiome seems to play a key role in promoting liver diseases and the development of HCC and evidence still increases [ 4].
The liver is closely linked to the gut, due to its anatomical connection via the portal vein. The liver receives nutrient-enriched blood from the intestine; it is also the first target of the intestinal microbiota and microbe-associated molecular patterns (MAMPs). MAMPs can trigger inflammatory responses via pattern-recognition receptors (PRRs) and microbial metabolites [ 5]. In healthy individuals, the hepatic exposure to pro-inflammatory MAMPs is limited due to the multilayer intestinal barrier. Alterations of the gut microbiota in CLD lead to a failing gut barrier via chronic inflammation. This process is a key mechanism leading to the progression of liver diseases and inferentially increases the risk of HCC development [ 68].

Bacterial dysbiosis in liver cirrhosis

Increasing evidence points to a key role of the gut microbiota in the development of CLD [ 9]. There are several animal studies showing a clear association between CLD and microbial dysbiosis. These findings could be confirmed by human data. There is strong evidence that the progression of NAFLD, ALD and chronic viral hepatitis is strongly associated with gut microbiome dysbiosis. In patients suffering from HBV and HCV, microbial diversity is decreased in comparison to health controls [ 10]. The complex network between NAFLD and dysbiosis is highlighted in multiple studies [ 9, 11, 12] and is also seen in patients suffering from ALD—microbiome alterations were associated with decreased levels of butyrate-producing Clostridiales species and increased levels of pro-inflammatory Enterobacteriaceae. Bacteroidales were reduced in patients diagnosed with cirrhosis [ 13]. Enterococcus faecalis is strongly correlated with the severity of liver disease and with mortality in patients suffering from alcoholic hepatitis [ 14]. In one study, bacteriophages targeting cytolytic Enterococcus faecalis, abolished induced liver disease in humanized mice [ 15]. Phages might therefore be a novel therapeutic approach in treating patients with alcoholic liver disease.
Furthermore, the microbiome influences progression from pre-existing diseases into cirrhosis, which emphasizes the central role for dysbiosis in the development of end stage liver disease in murine models as well as in human patients [ 16, 17].
Patients with advanced liver disease and cirrhosis have an alteration in the gut microbiome. These alterations are associated with an increase of potentially pathogenic bacteria and reduced numbers of bacteria with beneficial properties [ 18].
The composition of the intestinal microbiota in cirrhosis include enrichment of Veillonella or Streptococcus, as well as decreased numbers from the order Clostridiales [ 18]. In another study, in patients suffering from cirrhosis, the gut microbiome presented with a relative reduction in Bacteroidetes, an increase in Proteobacteria and Fusobacteria. Changes in Firmicutes mimicked the microbiome from healthy individuals [ 19]. Furthermore, there were differences at the family level, with Streptococcaceae and Veillonellaceae. Streptococcaceae positively correlated with cirrhosis severity, while Lachnospiraceae negatively correlated with disease activity. These differences were confirmed by another research group in a larger population of patients suffering from cirrhosis [ 19, 20].
An invasion of the gut from the mouth in patients with liver cirrhosis is most likely: the majority of enriched species were of buccal origin [ 18]. Furthermore, the abundance of buccal origin species in cirrhosis is associated with the use of proton pump inhibitors (PPIs). PPIs modulate microbiota composition in patients with CLD [ 21]. Besides alterations in the gut microbiome, bacterial overgrowth in the upper gastrointestinal tract, which is associated with increased circulating lipopolysaccharide (LPS) levels, seems to play a major role in the development of CLD [ 22]. Due to the close anatomic position of the small intestine to the liver, bacterial translocation in the upper gastrointerstinal tract is important in the pathogenesis of liver disease. Differences in the duodenal and salivary microbiota between patients suffering from cirrhosis and healthy individuals have been demonstrated in different studies. Qualitative and quantitative changes in the upper gastrointestinal tract might be linked to changes in the more distal microbiota. It is most likely that these findings point out that microbial changes in the upper gastrointestinal tract contribute to the complex pathophysiology of CLD as well as in the development of HCC [ 23].
Alteration in the microbiome in patients suffering from CLD are not only established in feces, but also in serum, saliva, sigmoid colonic mucosa, small intestinal mucosa, ascites and liver tissue [ 19]. Furthermore, dysbiosis is connected to main comorbidities of cirrhosis, including hepatic encephalopathy, spontaneous bacterial peritonitis, and multiple organ failure leading to death [ 20]. This evidence supports the conclusion that dysbiosis in cirrhosis causes holistic mucosal immune change and vice versa. Furthermore, emerging evidence also points towards the important roles of archaea, viruses, fungi and especially bacteriophages [ 24]. Further studies are needed to investigate and define the holistic changes in the microbiome in liver diseases.

HCC and microbiota

Dysbiosis plays a key role in the development of liver disease and HCC. In mouse models and humans with CLD and HCC high circulation LPS-levels were demonstrated, implicating the presence of an impaired intestinal barrier during multiple stages of CLD and in hepatocarcinogenesis [ 25, 26]. In animal models an impaired intestinal barrier played a key role in hepatocarcinogenesis via LPS and its receptor toll like receptor (TLR) 4 [ 17]. “Leaky gut” is associated with increased bacterial translocation and generates a chronic inflammatory state in the liver. Hepatocarcinogenesis via LPS resulting from an impaired intestinal barrier is driven via multiple cellular targets including HSCs, the hepatocyte-tumor compartment and Kupffer cells. The inflammatory responses in the liver are mediated via interaction between MAMPs and host PRRs, specifically the TLRs ([ 27]; Fig.  1). These pathways of pathogenesis have been demonstrated in several animal models. Only a few clinical trials correlating microbiota and HCC are published and show different alterations of the gut microbiota in patients with HCC. An increase in fecal Eschericha coli was associated with the presence of HCC in cirrhotic patients, suggesting that an intestinal enrichment of Eschericha coli could contribute to the process of hepatocarcinogenesis [ 28]. Results were confirmed in another study. In HCC patients suffering from hepatitis B or hepatitis C as underlying disease, more potential pro-inflammatory bacteria ( Escherichia, Shigella, Enterococcus) and reduced levels of Faecalibacterium, Ruminococcus, and Ruminoclostridium were observed and results in a decrease of potentially anti-inflammatory short-chain fatty acids [ 29]. In another study, patients with NAFLD-related cirrhosis and HCC, NAFLD-related cirrhosis without HCC, and healthy controls were compared. An increase of pro-inflammatory cytokines in the plasma of patients with HCC compared those without HCC was detected. The fecal microbiota of the cirrhosis group showed higher abundance of Enterobacteriaceae and Streptococcus and a reduction in Akkermansia. Bacteroides and Ruminococcaceae were increased in the HCC group, while Bifidobacterium was reduced [ 8]. In a study of early HCC, patients with or without cirrhosis where compared. Microbial diversity was significantly increased in HCC patients without signs of cirrhosis. The phylum Actinobacteria was increased in early HCC compared to patients with liver cirrhosis. In early HCC, thirteen genera including Gemmiger and Parabacteroides were enriched versus HCC with cirrhosis. Furthermore, LPS producing species Parabacteroides, were increased and the butyrate-producing species Actinobacteriae were decreased in patients with HCC compared to healthy individuals. Current evidence suggests that a specific microbiota pattern for patients with HCC does exist [ 30].

Conclusion

The intestinal microbiota and its alterations are strongly associated with CLD and the development of HCC. The alterations in intestinal microbiota create a pro-inflammatory hepatic milieu. The mechanisms and interactions leading to hepatic inflammation are diverse. First, dysbiosis leads to an impaired intestinal barrier that enhances TLR-mediated chronic liver inflammation and, second, altered and potentially pro-inflammatory bacterial metabolites are promoted by an impaired intestinal barrier. Whether altered bacterial metabolites or chronic inflammation are associated with the translocation of MAMPs from the impaired intestinal barrier are key players in hepatocarcinogenesis is subject of current research. It is highly suggestive that the impaired gut barrier and the dysbiosis act synergistically in the development of HCC. Furthermore, HCC might be associated with a specific gut microbiome signature. The current understanding of the interactions between dysbiosis, chronic liver disease and HCC are mainly due to preclinical studies and fecal samples from patients suffering from liver diseases. There is a tremendous need for human microbiome studies to substantiate the key role of the intestinal microbiome in the pathogenesis of HCC. Such studies could lead to a potential therapy for this highly lethal human disease.
Take home massage
The intestinal microbiota is a key player in hepatocarcinogenesis. Influencing the microbiota could lead to potential novel treatment strategies in this highly lethal disease.

Conflict of interest

M. Effenberger and H. Tilg declare that they have no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2020

memo - Magazine of European Medical Oncology 2/2020 Zur Ausgabe